Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tango Therapeutics Inc.

8.47
+1.3318.63%
Post-market: 8.630.1600+1.89%18:23 EDT
Volume:3.43M
Turnover:27.93M
Market Cap:942.37M
PE:-6.41
High:8.59
Open:7.25
Low:7.25
Close:7.14
52wk High:8.80
52wk Low:1.03
Shares:111.26M
Float Shares:35.08M
Volume Ratio:1.70
T/O Rate:9.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3218
EPS(LYR):-1.1929
ROE:-76.09%
ROA:-31.74%
PB:6.98
PE(LYR):-7.10

Loading ...

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

GlobeNewswire
·
Oct 06

BRIEF-Healthcare Veteran David Wilkinson To Join Tango As Chief Financial Officer

Reuters
·
Oct 01

Healthcare Veteran David Wilkinson to Join Tango as Chief Financial Officer

THOMSON REUTERS
·
Oct 01

Third Rock Ventures IV, L.P. Reports Disposal of Common Shares of Tango Therapeutics Inc

Reuters
·
Sep 30

Barclays Sticks to Their Buy Rating for Tango Therapeutics (TNGX)

TIPRANKS
·
Sep 26

Third Rock Ventures IV Reports Disposal of Common Shares in Tango Therapeutics Inc

Reuters
·
Sep 10

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

GlobeNewswire
·
Aug 26

Douglas Barry Resigns as Chief Legal and Compliance Officer of Tango Therapeutics, Effective September 12, 2025

Reuters
·
Aug 26

Third Rock Ventures IV, L.P. Reports Disposal of Common Shares of Tango Therapeutics Inc

Reuters
·
Aug 22

Tango Therapeutics Initiated at Overweight by Piper Sandler

Dow Jones
·
Aug 19

Stock Track | Tango Therapeutics Soars 5.12% on Positive Clinical Trial Updates and Strong Financial Position

Stock Track
·
Aug 05

Tango Therapeutics Q2 EPS $(0.35) Beats $(0.36) Estimate, Sales $3.181M Miss $6.679M Estimate

Benzinga
·
Aug 05

Tango Therapeutics Inc: Co Expects to Fund Operations Into Q1 of 2027

THOMSON REUTERS
·
Aug 05

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire
·
Aug 05

Tango Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
Aug 01

Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

GlobeNewswire
·
Jul 22

Tango Therapeutics Inc. Unveils New Strategies in Targeted Oncology Therapies with Promising Clinical Updates

Reuters
·
Jul 01

Tango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer Trial

Dow Jones
·
Jun 27

BRIEF-Tango Therapeutics Announces First Patient Dosed In Phase 1/2 Trial Of Tng462 Plus Revolution Medicines’ Daraxonrasib

Reuters
·
Jun 27

Barbara Weber Resigns from Revolution Medicines Inc. Board Ahead of 2025 Stockholders Meeting

Reuters
·
Jun 19